IGM Biosciences has announced that the focus of its exclusive worldwide collaboration agreement with Sanofi will now shift to developing immunoglobin M (IgM) agonist antibodies solely for immunology and inflammation indications.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,